Additional file 1 of The Determining Effective Testing in Emergency Departments and Care Coordination on Treatment Outcomes (DETECT) for Hepatitis C (Hep C) Screening Trial: rationale and design of a multi-center pragmatic randomized clinical trial of hepatitis C screening in emergency departments
التفاصيل البيبلوغرافية
العنوان:
Additional file 1 of The Determining Effective Testing in Emergency Departments and Care Coordination on Treatment Outcomes (DETECT) for Hepatitis C (Hep C) Screening Trial: rationale and design of a multi-center pragmatic randomized clinical trial of hepatitis C screening in emergency departments
Additional file 1: Table S1. Simulated results to estimate sample size and power using summary estimates weighted by contributions to enrollment form each site from the trial at 58.6% of target enrollment. Each simulation represents 1,000 simulated trials using Monte Carlo methods. Table S2. Simulated results to estimate sample size and power using summary estimates inverse probability weighted by contributions to enrollment from each site from the trial at 58.6% of target enrollment. Each simulation represents 1,000 simulated trials using Monte Carlo methods. Table S3. Two-way data tables of nontargeted versus targeted HCV antibody positive prevalence based on relative proportions of HCV tests performed in each of the two study arms. Light gray shaded values indicate combinations that contribute to an aggregate prevalence ranging from 5.1% to 6.8%, the 95% confidence intervals of the weighted aggregate Ab+ prevalence estimate. Dark gray shaded values indicate combinations that contribute to an aggregate prevalence of 4.7%, based on inverse probability weighting. Figure S1. Pragmatic-Explanatory Continuum Indicator Summary (PRECIS)-2 wheel diagram for The DETECT Hep C Screening Trial. Figure S2. Data components and flow of data for The DETECT Hep C Screening Trial. Figure S3. A. Eligibility Best Practice Advisory (BPA). B. Nontargeted HCV test offer BPA. C. Targeted HCV screening questions BPA. D. Targeted HCV test offer BPA. Sample Monitoring Figures. Protocol (Version 3.3, Date February 17, 2022).
